Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuronetics, Inc. - Common Stock (NQ:STIM)

3.810 -0.010 (-0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neuronetics, Inc. - Common Stock

< Previous 1 2 3 Next >
NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards
Award Acknowledges Excellence in Digital Marketing Efforts 
From Neuronetics
Via GlobeNewswire
Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform
New automated features elevate the standard of care for NeuroStar® Advanced Therapy practices 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Expanded TMS Therapy Access Through Aetna® Health Plans
Policy Updates Impact Nationwide Commercial Plans for 16.8 Million Covered Lives 
From Neuronetics
Via GlobeNewswire
NeuroStar Achieves Milestone Regulatory Clearance in South Korea
First International Approval for Expanded Indication and Certification for MT Cap and D-Tect™ Technologies 
From Neuronetics
Via GlobeNewswire
NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player
Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment 
From Neuronetics
Via GlobeNewswire
Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy
The Company expands technology for patients with obsessive-compulsive disorder 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan
Lower Medication Requirement Helps Depression Patients Obtain Treatment Sooner 
From Neuronetics
Via GlobeNewswire
New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction
Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy 
From Neuronetics
Via GlobeNewswire
Neuronetics Wins 2023 Bell Seal for Workplace Mental Health
The Company is recognized for its commitment to employees’ well-being 
From Neuronetics
Via GlobeNewswire
Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR
Achievement demonstrates Company’s commitment to rigorous standards for safe and effective products 
From Neuronetics
Via GlobeNewswire
Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting
Data highlights the Company’s commitment to advancing TMS and improving patient outcomes 
From Neuronetics
Via GlobeNewswire
NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month
Campaign features patients’ experiences to support others with depression 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
Strategic role strengthens NeuroStar® Advanced Therapy commercialization team 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Expanded TMS Access through United HealthCare
UHC Medicare Advantage plans in NGS states expand access via NPPs 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy
BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMS 
From Neuronetics
Via GlobeNewswire
NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities
Fifth FDA clearance in less than two years offers greater connectivity and flexibility to improve the patient and provider experience 
From Neuronetics
Via GlobeNewswire
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
Award recognizes NeuroStar for its significant contributions toward patient wellbeing 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives
United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients 
From Neuronetics
Via GlobeNewswire
Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
Company Launches a New Educational Campaign For Providers 
From Neuronetics
Via GlobeNewswire
Neuronetics Sponsors the 5th International Brain Stimulation Conference
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer
New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners
NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety 
From Neuronetics
Via GlobeNewswire
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
NeuroStar’s technology once again recognized as an effective non-drug treatment for patients 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy 
From Neuronetics
Via GlobeNewswire
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS 
From Neuronetics
Via GlobeNewswire
Artificial Intelligence Could Be About To Replace Your Doctor
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector
FN Media Group Presents Oilprice.com Market Commentary London – October 18, 2021 – A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Law Offices of Frank R. Cruz Announces Investigation of Neuronetics, Inc. (STIM) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.